Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This pilot clinical trial studies imaging during surgery in diagnosing patients with prostate, bladder, or kidney cancer. New diagnostic imaging procedures, may find prostate, bladder, or kidney cancer

Official Title

Utility of Fluorescence and Photoacoustic Imaging Intraoperatively to Assist With Robotic Assisted Minimally Invasive Surgery

Eligibility Criteria

Ages Eligible for Study: 18 Years to 85 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Patients must have a pathologic confirmation of prostate cancer, bladder cancer, or kidney cancer based on previous biopsies or procedures OR a strong concern for a kidney malignancy based on computed tomography (CT) or magnetic resonance imaging (MRI) imaging - Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
  1. - Patients with a surgical history or anatomic variant that would preclude robot assisted laparoscopic approaches to their surgery (i.e. history of ventral hernia repair with mesh) - Patients with medical co-morbidities who cannot tolerate laparoscopic surgery secondary to intra-abdominal carbon dioxide insufflation - Patients with documented allergy or adverse drug reaction to indocyanine green or baseline serum creatinine greater than 1.5 mg/dL


James D. Brooks
James D. Brooks
Surgical oncologist, Urologic surgeon
Keith and Jan Hurlbut Professor
Sanjiv Sam Gambhir, MD, PhD
Harcharan Gill
Harcharan Gill
Urologic oncologist, Urologist, Genitourinary specialist, Urologic surgeon
Kathryn Simmons Stamey Professor, Emeritus
Nishita Kothary, MD
Nishita Kothary, MD
Interventional radiologist
Professor of Radiology (Interventional Radiology)
Benjamin I. Chung
Benjamin I. Chung
Urologic oncologist, Urologic specialist, Urologist, Genitourinary specialist, Urologic surgeon
Associate Professor of Urology

Contact us to find out if this trial is right for you.


Mark Gonzalgo